Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1000
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1000
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

499
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
499
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

506
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
506
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

441
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
441
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

831
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
831

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.

Multiple sclerosis and related disorders·2020
Same author

Surveillance of foodborne botulism in Poland: 1960-1998.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2003
Same author

The changing epidemiology of diphtheria in the vaccine era.

The Journal of infectious diseases·2000
Same author

Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learned.

The Journal of infectious diseases·2000
Same author

Implications of the diphtheria epidemic in the Former Soviet Union for immunization programs.

The Journal of infectious diseases·2000
Same author

[Wide spread inflammation of the parotid glands (mumps): underestimated disease. I. Epidemiology of the mumps and its medical meaning in Poland].

Przeglad epidemiologiczny·1999
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
Same journal

Indonesia's health reform: from pandemic mandate to the six pillars of transformation.

Lancet (London, England)·2026
Same journal

LGBTQ+ Russians increasingly avoiding doctors.

Lancet (London, England)·2026
Same journal

Department of Error.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jan 19, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.5K

Interferon beta treatment for multiple sclerosis

A Galazka

    Lancet (London, England)
    |February 16, 1999
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
    09:38

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

    Published on: September 12, 2016

    12.7K
    High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
    10:00

    High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

    Published on: March 24, 2015

    13.8K

    Related Experiment Videos

    Last Updated: Jan 19, 2026

    Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
    08:26

    Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

    Published on: June 14, 2018

    12.5K
    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
    09:38

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

    Published on: September 12, 2016

    12.7K
    High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
    10:00

    High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

    Published on: March 24, 2015

    13.8K